A practical reference on epithalamin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
In its supplied form epitalon is a white to off-white powder, usually lyophilized and often hygroscopic. It dissolves readily in water and in aqueous buffers, and it is commonly handled as the acetate or trifluoroacetate salt to improve stability during purification and drying. The amide backbone is labile in aqueous media, so solutions are less durable than the dry solid. Handling notes in the chemical literature therefore emphasize keeping the powder dry, cool and shielded from light until it is dissolved.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four residues, linear chain |
| Residue sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG |
| Calculated mass | 390.3 daltons | Value for the free, uncharged form |
| Appearance | White to off-white powder | Usually supplied lyophilized |
| Solubility | Freely soluble in water | Often handled as a salt form |
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Although the term was coined in the late 1980s one of the first retroactively recognized examples of a killer application is the VisiCalc spreadsheet, released in 1979 for the Apple II. Because it was not released for other computers for 12 months, people spent US$100 (equivalent to $400 in 2025) for the software first, then $2,000 to $10,000 (equivalent to $9,000 to $44,000) on the requisite Apple II. Byte wrote in 1980, "VisiCalc is the first program available on a microcomputer that has been responsible for sales of entire systems", and Creative Computing's VisiCalc review is subtitled "reason enough for owning a computer". Others also chose to develop software, such as EasyWriter, for the Apple II first because of its higher sales, helping Apple defeat rivals Commodore International and Tandy Corporation. The co-creator of WordStar, Seymour Rubinstein, argued that the honor of the first killer app should go to that popular word processor, given that it came out a year before VisiCalc and that it gave a reason for people to buy a computer. However, whereas WordStar could be considered an incremental improvement (albeit a large one) over smart typewriters like the IBM Electronic Selectric Composer, VisiCalc, with its ability to instantly recalculate rows and columns, introduced an entirely new paradigm and capability unavailable on larger computers. Lotus 1-2-3 similarly benefited sales of the IBM PC. Noting that computer purchasers did not want PC compatibility as much as compatibility with certain PC software, InfoWorld suggested "let's tell it like it is.
== References == Aldose reductase inhibitor for treatment of diabetic complications. Prepn (stereo unspec): M. Kurono, et al., EP 193415; eidem, US 4740517 (1986, 1988 both to Sanwa) Prepn of isomers: T. Yamaguchi et al., Arzneim.-Forsch. 44, 344 (1994) Pharmacological profile: K. Mizuno et al. in Current Concepts of Aldose Reductase and Its Inhibitions, N. Sakamoto et al., Eds. (Elsevier, Amsterdam, 1990) pp 89–96. Configuration and crystal structure of complex with aldose reductase: M. Oka et al., J. Med. Chem. 43, 2479 (2000). Clinical efficacy in diabetic peripheral neuropathy: N. Hotta et al., Diabetes Care 24, 1776 (2001). Clinical suppression of sorbitol accumulation in erythrocytes of diabetic patients: T. Asano et al., J. Diabetes Complications 16, 133 (2002); eidem, ibid. 18, 336 (2004). Review of clinical development: N. Giannoukakis, Curr. Opin. Invest. Drugs 4, 1233-1239 (2003).
There is a difference between the al-Houthi family and the Houthi movement. The movement was called by their opponents and foreign media "Houthis". The name came from the surname of the early leader of the movement, Hussein al-Houthi, who died in 2004. Membership of the group had between 1,000 and 3,000 fighters as of 2005 and between 2,000 and 10,000 fighters as of 2009. In 2010, the Yemen Post claimed that they had over 100,000 fighters. According to Houthi expert Ahmed Al-Bahri, by 2010, the Houthis had a total of 100,000–120,000 followers, including both armed fighters and unarmed loyalists. As of 2015, the group is reported to have attracted new supporters from outside their traditional demographics.
== Law == Charitable lead trust, a form of charitable trust in the United States Community land trust, a housing model Consolidation of Labor Laws, a 1943 Brazilian law (Portuguese: Consolidação das Leis do Trabalho)
=== Discovery chemistry === BioDuro’s chemistry division supports medicinal chemistry, hit-to-lead, lead optimization, and synthetic route development. Its laboratories carry out small-molecule synthesis, peptide synthesis, and bioconjugation, including payload–linker development for antibody- drug conjugate (ADC) programs. The chemistry group works closely with DMPK and biology teams to support iterative design and structure- activity relationship (SAR) cycles.
Sources: en.wikipedia.org
=== Other conditions === Previous hand injury Ledderhose disease (plantar fibromatosis) Epilepsy (possibly due to anti-convulsive medication) Higher-than-average fasting blood glucose level Diabetes mellitus HIV Macrophallism Previous myocardial infarction
== Isolation of Osteoblasts == The first isolation technique by microdissection method was originally described by Fell et al. using chick limb bones which were separated into periosteum and remaining parts. She obtained cells which possessed osteogenic characteristics from cultured tissue using chick limb bones which were separated into periosteum and remaining parts. She obtained cells which possessed osteogenic characteristics from cultured tissue. Enzymatic digestion is one of the most advanced techniques for isolating bone cell populations and obtaining osteoblasts. Peck et al. (1964) described the original method that is now often used by many researchers. In 1974 Jones et al. found that osteoblasts moved laterally in vivo and in vitro under different experimental conditions and described the migration method in detail. The osteoblasts were, however, contaminated by cells migrating from the vascular openings, which might include endothelial cells and fibroblasts.
Classical EDS is characterized by extremely elastic skin that is fragile and bruises easily, and hypermobility of the joints. Molluscoid pseudotumors (calcified hematomas that occur over pressure points) and spheroids (cysts that contain fat occurring over forearms and shins) are also often seen. A side complication of the hyperelasticity presented in many EDS cases makes wound closure on its own more difficult. Sometimes, motor development is delayed and hypotonia occurs. The variation causing this type of EDS is in the genes COL5A2, COL5A1, and less frequently COL1A1. It involves the skin more than hEDS. In classical EDS, large variation in symptom presentation is seen. Because of this variance, EDS has often been underdiagnosed. Without genetic testing, healthcare professionals may be able to provide a provisional diagnosis based on careful examination of the mouth, skin, and bones, as well as by neurological assessment. A good way to begin the diagnostic process is by reviewing a person's family history. EDS is an autosomal dominant condition, so it is often inherited from parents. Genetic testing remains the most reliable way to diagnose EDS. No cure for type 1 EDS has been found, but a course of non-weight-bearing exercise can help with muscular tension, which can help correct some EDS symptoms. Anti-inflammatory drugs and lifestyle changes can help with joint pain. Lifestyle choices should also be made with children who have EDS to try to prevent wounds to the skin. Protective garments can help with this.
Cristina Scabbia - vocals Andrea Ferro - vocals and grunts Marco Biazzi - guitar Cristiano Migliore - guitar Marco Coti Zelati - bass, keyboards, programming, design, layout design Cristiano Mozzati - percussion, drums, programming
Sources: en.wikipedia.org
The peptide contains four residues in the order alanine, glutamate, aspartate and glycine, abbreviated AEDG. The chain is linear and held together by three peptide bonds. Its calculated mass for the uncharged free form is about 390.3 daltons.
Epithalamin refers to a crude preparation derived from bovine pineal tissue, which contains many components. Epitalon is a single synthetic tetrapeptide identified from that material and produced by chemical synthesis. The two names are sometimes confused because early reports treated the synthetic peptide as an active fragment of the extract.
It has been registered for clinical use in Russia, where it is associated with a small family of short peptides. In most other jurisdictions it is not an approved medicine and is traded as a research chemical. Regulatory status varies by country and changes over time.
It is a four-amino-acid peptide built from alanine, glutamate, aspartate and glycine in that order. Its formula is C14H22N4O9, and it is made by chemical synthesis rather than extracted from tissue. The synthetic peptide is a single defined molecule, unlike the pineal extracts it is often compared with.